申请人:Merck Sharp & Dohme Corp.
公开号:US08193228B2
公开(公告)日:2012-06-05
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
某些新型取代咪唑是人类炸弹素受体的配体,特别是人类炸弹素受体亚型-3(BRS-3)的选择性配体。因此,它们可用于治疗、控制或预防对BRS-3调节敏感的疾病和障碍,如肥胖症和糖尿病。